Abstract
Background
As the molecular mechanisms of Cytarabine, one of the most important drugs used in the leukaemia’s treatment, are only partially understood and the role of autophagy on leukaemia development and treatment is only recently being investigated, in this study, by using Chloroquine (CQ) and 3-methyladenine (3MA) as autophagy inhibitors, we aim to evaluate the contribution of an autophagic mechanism to Cytarabine (AraC)-induced death of HL60 leukaemia cells.
Methods
Trypan blue exclusion and AnnexinV/PI assays were used to evaluate HL60 cell death under AraC treatment in the presence or absence of 3MA and CQ. Western blotting and immunofluorescence experiments were performed to show the involvement of apoptosis and autophagy protein expressions. Phenotypic characterization of HL60-treated cells was performed by using immunophenotyping. Clonogenic assays were applied to analyse clonal function of HL60-treated cells.
Results
We observed that although autophagy inhibition by 3MA, but not CQ, increased the death of HL60 AraC cells after 24 h of treatment, no significant differences between AraC and AraC + 3MA-treated groups were observed by using clonogenic assay. In addition, increased number of immature (CD34+/CD38−Lin−/low) HL60 cells was found in AraC and AraC-3MA groups when compared with control untreated cells.
Conclusions
Although AraC anti-leukaemia effects could be potentiated by 3MA autophagy inhibition after 24 h of exposure, leukaemia cell resistance, the main causes of treatment failure, is also promoted by autophagy initial stage impairment by 3MA, denoting the complex role of autophagy in leukaemia cells’ response to chemotherapy.
Similar content being viewed by others
References
Ablain J, Leiva M, Peres L, Fonsart J, Anthony E, de Thé H (2013) Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp Med 210:647–653
Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI et al (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117:326–336
Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W et al (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17:654–665
Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA et al (2013) First line treatment with rituximab- Hyper-CVAD alternating with rituximab- Methotrexate- Cytarabine and followed by consolidation with 90Y-Ibritumomab-Tiuxetan in patients with mantle cell lymphoma. Results of a phase 2 pilot multicenter trial from the GELTAMO group. Haematologica 98:1563–1570
Bincoletto C, Bechara A, Pereira GJ, Santos CP, Antunes F, Peixoto da-Silva J et al (2013) Interplay between apoptosis and autophagy, a challenging puzzle: new perspectives on antitumor chemotherapies. Chem Biol Interact 206:279–288
Bonvillain RW, Painter RG, Adams DE, Viswanathan A, Lanson NA, Wang G (2010) RNA interference against CFTR affects HL60-derived neutrophil microbicidal function. Free Radic Biol Med 49:1872–1880
Boya P, González-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N et al (2005) Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25:1025–1040
Buytaert E, Callewaert G, Vandenheede JR, Agostinis P (2006) Deficiency in apoptotic effectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy 2:238–240
Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS et al (1983) Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1:763–771
Capizzi RL, Yang JL, Rathmell JP, White JC, Cheng E, Cheng YC et al (1985) Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation. Semin Oncol 12:65–74
Chee LC, Hendy J, Purton LE, McArthur GA (2013) ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells. Leukemia 27:1369–1380
Choi KD, Vodyanik M, Slukvin II (2011) Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat Protoc 6:296–313
Collins SJ, Gallo RC, Gallagher RE (1977) Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270:347–349
Drexler HG, Quentmeier H, MacLeod RA, Uphoff CC, Hu ZB (1995) Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. Leuk Res 19:681–691
Ekiz HA, Can G, Baran Y (2012) Role of autophagy in the progression and suppression of leukemias. Crit Rev Oncol Hematol 81:275–285
Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M et al (1995) PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res 1:583–590
Giansanti V, Torriglia A, Scovassi AI (2011) Conversation between apoptosis and autophagy: “Is it your turn or mine?”. Apoptosis 16:321–333
Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E et al (1994) Acute promyelocytic leukemia: from genetics to treatment. Blood 83:10–25
Gunji H, Kharbanda S, Kufe D (1991) Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-beta- D-arabinofuranosylcytosine. Cancer Res 51:741–743
Han C, Sun B, Wang W, Cai W, Lou D, Sun Y et al (2011) Overexpression of microtubule-associated protein-1 light chain 3 is associated with melanoma metastasis and vasculogenic mimicry. Tohoku J Exp Med 223:243–251
Janku F, McConkey DJ, Hong DS, Kurzrock R (2011) Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8:528–539
Kapuy O, Vinod PK, Mandl J, Bánhegyi G (2013) A cellular stress-directed bistable switch controls the crosstalk between autophagy and apoptosis. Mol BioSyst 9:296–306
Koeffler HP (1983) Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 62:709–721
Lamba JK (2011) Pharmacogenomics of cytarabine in childhood leukemia. Pharmacogenomics 12:1629–1632
Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463–477
Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132:27–42
Liliemark JO, Plunkett W, Dixon DO (1985) Relationship of 1-beta-Darabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 59-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res 45:5952–5957
Löwenberg B (2013) Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121:26–28
Lübbert M, Koeffler HP (1988) Myeloid cell lines: tools for studying differentiation of normal and abnormal hematopoietic cells. Blood Rev 2:121–133
Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW (1981) Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci USA 78:3235–3239
Marone M, Scambia G, Bonanno G, Rutella S, de Ritis D, Guidi F et al (2002) Transforming growth factor-1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects. Leukemia 16:94–105
Mehta K, McQueen T, Neamati N, Collins S, Andreeff M (1996) Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 7:179–186
Melnick A, Licht JD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167–3215
Mizushima N (2007) Autophagy: process and function. Genes Dev 21:2861–2873
Mizushima N, Levine B, Cuervo AM, Klionsky DJ (2008) Autophagy fights disease through cellular self-digestion. Nature 451:1069–1075
Moon DO, Asami Y, Kim MO, Jang JH, Kim BY, Ahn JS et al (2013) Xestospongin C induces monocytic differentiation of HL60 cells through activation of the ERK pathway. Food Chem Toxicol 55:505–512
Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N et al (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 22:927–939
Pelosi E, Castelli G, Martin-Padura I, Bordoni V, Santoro S, Conigliaro A et al (2012) Human haemato-endothelial precursors: cord blood CD34 + cells produce haemogenic endothelium. PLoS ONE 7:e51109
Plunkett W, Liliemark JO, Estey E, Keating MJ (1987) Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14:159–166
Raza A, Gezer S, Anderson J, Lykins J, Bennett J, Browman G et al (1992) Relationship of [3H] Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp Hematol 20:1194–1200
Rustum YM, Raymakers RA (2012) 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol Ther 56:307–321
Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G et al (2000) Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ 7:1263–1269
Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y et al (2010) Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 10:370–375
Smaili SS, Hsu YT, Sanders KM, Russell JT, Youle RJ (2001) Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane potential. Cell Death Differ 8:909–920
Solomon VR, Lee H (2009) Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 625:220–233
Toksoz D, Bunce CM, Stone PC, Michell RH, Brown G (1982) Variant cell lines from the human promyelocyte line HL60. Leuk Res 6:491–498
Vorbrodt A, Meo P, Rovera G (1979) Regulation of acid phosphatase activity in human promyelocytic leukemic cells induced to differentiate in culture. J Cell Biol 83:300–307
Wang WS, Tzeng CH, Chiou TJ, Liu JH, Hsieh RK, Yen CC et al (1997) High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin’s lymphoma. Jpn J Clin Oncol 27:154–157
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ (1997) Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139:1281–1292
Yang YP, Liang ZQ, Gao B, Jia YL, Qin ZH (2008) Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells. Acta Pharmacol Sin 29:123–134
Zayed A, Couban S, Hayne O, Sparavalo N, Shawwa A, Sadek I et al (2007) Acute promyelocytic leukemia: a novel PML/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance. Leuk Lymphoma 48:489–496
Acknowledgments
This study was supported by grants from Fundação do Amparo a Pesquisa do Estado de São Paulo (FAPESP—12/51215-4) and Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES) fellowship. The authors would like to thank Hanako Hirata, Maria de Lourdes L. dos Santos, Bruno Palmieri and Cıcero R. dos Santos for their technical support.
Conflict of interest
The authors have declared no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Palmeira-dos-Santos, C., Pereira, G.J.S., Barbosa, C.M.V. et al. Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine-induced death of leukaemia cells. J Cancer Res Clin Oncol 140, 909–920 (2014). https://doi.org/10.1007/s00432-014-1640-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-014-1640-4